Cargando…

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

INTRODUCTION: Inadequately controlled severe asthma patients require additional therapy accounting for significant clinical and economic burden. Our analysis aims to determine the cost-effectiveness of omalizumab in the management of severe allergic asthma in Italy based on observational data from t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canonica, Giorgio Walter, Colombo, Giorgio Lorenzo, Rogliani, Paola, Santus, Pierachille, Pitotti, Claudia, Di Matteo, Sergio, Martinotti, Chiara, Bruno, Giacomo Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986414/ https://www.ncbi.nlm.nih.gov/pubmed/32158289 http://dx.doi.org/10.2147/RMHP.S211321

Ejemplares similares

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
por: Canonica, Giorgio Walter, et al.
Publicado: (2018)

Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2019)

Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA – an observational, 2 phase, patient reported outcomes study
por: Canonica, Giorgio Walter, et al.
Publicado: (2015)

Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis
por: Heffler, Enrico, et al.
Publicado: (2020)

Plasma Galectin-3 and urine proteomics predict FEV(1) improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study()
por: Riccio, Anna Maria, et al.
Publicado: (2020)

Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and Xolair(®) In the Management of Asthma) study
por: Colombo, Delia, et al.
Publicado: (2019)

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
por: Canonica, Giorgio Walter, et al.
Publicado: (2019)

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps
por: Bagnasco, Diego, et al.
Publicado: (2022)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives
por: Torre, Enrico, et al.
Publicado: (2022)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
por: Colombo, Giorgio L, et al.
Publicado: (2018)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
por: Bergantini, Laura, et al.
Publicado: (2021)

276 A 4-Year Follow-up in Children With Moderate/Severe Asthma after Withdrawal 1 Year Omalizumab Treatment
por: Teijeiro, Alvaro, et al.
Publicado: (2012)

La próxima guerra
por: Bratt, K. A. (Karl Axel), b. 1882
Publicado: (1932)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Is allergic sensitization relevant in severe asthma? Which allergens may be culprit?
por: Lombardi, Carlo, et al.
Publicado: (2017)

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II
por: Torre, Enrico, et al.
Publicado: (2020)

Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy
por: Ruggeri, Isabella, et al.
Publicado: (2012)

Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy
por: Colombo, Giorgio L, et al.
Publicado: (2012)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
por: Zafari, Zafar, et al.
Publicado: (2018)

Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
por: Nishima, Sankei, et al.
Publicado: (2019)

Omalizumab for the treatment of severe allergic asthma in children: A tale of two
por: Brannick, Sinéad, et al.
Publicado: (2022)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
por: Torres-Duque, Carlos A., et al.
Publicado: (2022)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
por: Tajiri, Tomoko, et al.
Publicado: (2023)

Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
por: Curtiss, Frederic R.
Publicado: (2005)

Day and Night Control of COPD and Role of Pharmacotherapy: A Review
por: Braghiroli, Alberto, et al.
Publicado: (2020)

Physicians’ prescribing behaviour and clinical practice patterns for allergic rhinitis management in Italy
por: Passalacqua, Giovanni, et al.
Publicado: (2020)

Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months
por: Riccio, Anna Maria, et al.
Publicado: (2017)

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
por: Pelaia, Corrado, et al.
Publicado: (2021)

Appropriateness in allergic respiratory diseases health care in Italy: definitions and organizational aspects
por: Lombardi, Carlo, et al.
Publicado: (2016)

Early consensus management for non-ICU acute respiratory failure SARS-CoV-2 emergency in Italy: from ward to trenches
por: Vitacca, Michele, et al.
Publicado: (2020)

155 Omalizumab Improves Asthma but not Nasal Symptoms in Japanese Patients With Severe Allergic Asthma and Rhinitis
por: Nishihara, Fuyumi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_b46n11tlipu4tto6iss8adj4nh